Abbott Laboratories
ABT
$132.78
$0.780.59%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.64% | 8.16% | 478.98% | 14.62% | -5.31% |
| Total Depreciation and Amortization | -3.48% | -6.09% | -0.74% | -2.79% | 0.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.71% | -4.93% | 147.08% | 0.00% | 6.82% |
| Change in Net Operating Assets | -126.04% | 27.20% | -2,084.91% | 128.20% | 73.91% |
| Cash from Operations | 4.44% | 38.24% | -5.60% | 44.11% | 62.93% |
| Capital Expenditure | 5.82% | -21.61% | 4.64% | 0.71% | -5.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -97.50% |
| Other Investing Activities | -163.29% | 151.85% | -111.59% | -65.22% | -1.25% |
| Cash from Investing | -28.48% | -10.59% | -5.10% | 6.31% | 62.65% |
| Total Debt Issued | -99.10% | -- | -95.45% | -- | 22,000.00% |
| Total Debt Repaid | 72.13% | -716.54% | 36.11% | 102.79% | -654.55% |
| Issuance of Common Stock | 169.23% | 114.18% | -26.47% | 64.29% | -13.33% |
| Repurchase of Common Stock | -100.00% | -23.89% | -21.62% | -37,450.00% | 99.30% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.08% | -7.21% | -7.88% | -8.11% | -7.98% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -38.69% | -74.74% | 9.31% | 32.65% | 38.63% |
| Foreign Exchange rate Adjustments | 492.31% | 166.67% | -432.00% | 224.14% | 51.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -40.40% | -77.12% | -68.98% | 150.71% | 153.02% |